jRCT2051220121进行中（未招募）不适用
Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity (REDEFINE 1)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 250
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •BMI >= 30.0 kg/m2 or b) BMI >= 27.0 kg/m2 with the presence of at least one weight related comorbidity including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
排除标准
- •History of type 1 or type 2 diabetes mellitus
结局指标
主要结局
-
Change from baseline in body weight (%)
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A research study to see how well CagriSema helps people losing weight in people who have a body weight above the healthy range and type 2 diabetesOverweight, Obesity and Diabetes Mellitus, Type 2MedDRA version: 24.1Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-005121-24-IEovo Nordisk A/S1,200
进行中（未招募）
3 期
Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesityObesityJPRN-jRCT2051220121Oyatani Akihito250
进行中（未招募）
1 期
A research study to see how well CagriSema helps people losing weight in people who have a body weight above the healthy range and type 2 diabetesOverweight, Obesity and Diabetes Mellitus, Type 2MedDRA version: 24.1Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2021-005121-24-HUovo Nordisk A/S1,200
进行中（未招募）
3 期
A research study to see how well CagriSema helps people with excess body weight lose weightCTRI/2022/12/048201ovo Nordisk AS
已完成
不适用
Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in East Asian participants with overweight or obesity(NN9838-4762) (REDEFINE 5)ObesityjRCT2031220734Novo Nordisk Pharma Ltd.320